Status:
COMPLETED
eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Hepatitis C
Renal Disease
Eligibility:
All Genders
20+ years
Brief Summary
Data regarding the nephrotoxicity of sofosbuvir (SOF) remain controversial. The investigators compared the changes of estimated glomerular filtration rate (eGFR) in patients with chronic hepatitis C v...
Detailed Description
Chronic hepatitis C virus (HCV) infection is a major health problem that affects 71 million people worldwide. Patients with chronic HCV infection may present with various hepatic and extrahepatic mani...
Eligibility Criteria
Inclusion
- Chronic HCV patients receiving SOF-based or SOF-free DAAs for 12 weeks
Exclusion
- Decompensated cirrhosis (Child-Pugh B or C)
- Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73m2
- Active hepatocellular carcinoma (HCC)
- Organ transplantation
- Hepatitis B virus (HBV) co-infection
- Human immunodeficiency virus (HIV) co-infection
- Not received off-therapy follow-up till week 24
Key Trial Info
Start Date :
February 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2019
Estimated Enrollment :
441 Patients enrolled
Trial Details
Trial ID
NCT04047680
Start Date
February 1 2015
End Date
June 1 2019
Last Update
August 8 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital, Yun-Lin Branch
Douliu, Taiwan, 10002
2
National Taiwan University Hospital
Taipei, Taiwan, 10002